Zalevsky Jonathan's Form 4 filing
Nektar Therapeutics (NKTR) · filed Nov 25, 2025
- Accession no.
- 0001193125-25-297855
- Filed
- Nov 25, 2025
- Trade date
- Nov 21-25, 2025
- Filing delay
- 4 days
- Rule 10b5-1 plan
- Not checked
This filing lists 2 non-derivative transactions and 1 derivative transaction. Open-market sales total $62.8K. It was filed 4 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Zalevsky JonathanCIK 0001789857 | Officer (Chief R&D Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Common Stock | AGrant or awardAcquired | +2,666 | $0.00 | $0 | 20,128 | Direct | |
| Nov 25, 2025 | Common Stock | SSaleDisposed | −1,157 | $54.28F4 | −$62,801.96 | 18,971 | Direct |
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Nov 21, 2025 | Common Stock | AGrant or awardAcquired | +4,766 | $0.00 | $0 | 4,766 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F4
This transaction was executed in multiple trades at prices ranging from $58.26 to $59.56. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide full information regarding the number of shares and the prices at which the transactions were effected upon the request to the SEC staff, the Issuer, or a security holder of the Issuer.
Referenced by the price of 1 transaction in Table I.